EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Identification of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase

Donald T Moir

Current Drug Target -Infectious Disorders · 01.09.2005 · 5 (3) · 297-305

DOI: 10.2174/1568005054880154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Drug Target -Infectious Disorders, erschienen am 01.09.2005. Verfasst von Donald T Moir. Beteiligte Einrichtung: Microbiotix, Inc., One Innovation, Dr. Worcester, MA 01605, USA. dmoir@microbiotix.com. Die Arbeit wurde bisher 39-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FabI-related enoyl-ACP reductase enzymes of bacteria meet many of the criteria for antibacterial targets. These enzymes are essential for the growth of several pathogenic species, have no significant mammalian homologs, catalyze a rate-limiting step in a vital macromolecular biosynthetic pathway, and are already the targets of antibacterials used in the clinic (isoniazid) and in consumer products (triclosan). The suitability of FabI as an antibiotic target is diminished somewhat by the discovery that many pathogens carry an alternate unrelated enoyl-ACP reductase (FabK) or both reductases. However, a key human pathogen, Staphylococcus aureus and its increasingly common drug-resistant derivative MRSA are sensitive to FabI inhibitors. Screening for inhibitors of this target has resulted in the identification of five chemical classes of potent inhibitors. In addition, analogs of triclosan with increased potency and with pro-drug features have been engineered. At least one of these classes of inhibitors has been optimized and tested in animals for pharmacokinetic properties and efficacy. Further development of one or more of these classes and further screening are expected to generate new FabI inhibitors for application in the clinic against drug-resistant S. aureus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug Resistance, BacterialEnzyme InhibitorsForecastingHumansMolecular StructureStaphylococcus aureusStructure-Activity RelationshipTriclosan

Substanzen

Anti-Bacterial AgentsEnzyme InhibitorsTriclosan

Autor:innen und Institutionen

  • Microbiotix, Inc., One Innovation, Dr. Worcester, MA 01605, USA. dmoir@microbiotix.com

Zitieren

APA

Moir, D. T. (2005). Identification of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase. Current Drug Target -Infectious Disorders, 5(3), 297-305. https://doi.org/10.2174/1568005054880154

Vancouver

Moir DT. Identification of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase. Current Drug Target -Infectious Disorders. 2005;5(3):297-305. doi:10.2174/1568005054880154

BibTeX
@article{Moir2005,
  author = {Moir, Donald T},
  title = {Identification of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase},
  journal = {Current Drug Target -Infectious Disorders},
  year = {2005},
  volume = {5},
  number = {3},
  pages = {297--305},
  doi = {10.2174/1568005054880154}
}
Kostenlos starten →